Advances in neuroscience.
Balfe
Andrew
A
Thomson Scientific, Middlesex House, 34-42 Cleveland Street, London, W1T 4JE, UK. andrew.balfe@thomson.com
Perry
Letitia
L
D000544:Alzheimer Disease / Q000188:drug therapy / Q000378:metabolism; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors / Q000378:metabolism; D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology; D014150:Antipsychotic Agents / Q000494:pharmacology; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors / Q000378:metabolism; D015507:Drugs, Investigational / Q000494:pharmacology* / Q000627:therapeutic use; D006727:Hormone Antagonists / Q000494:pharmacology; D006801:Humans; D009488:Neurosciences / Q000639:trends*; D011480:Protease Inhibitors / Q000494:pharmacology; D018094:Receptors, Metabotropic Glutamate / Q000037:antagonists & inhibitors; D014667:Vasopressins / Q000037:antagonists & inhibitors
D000700:Analgesics; D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D015507:Drugs, Investigational; D006727:Hormone Antagonists; D011480:Protease Inhibitors; D018094:Receptors, Metabotropic Glutamate; C104077:metabotropic glutamate receptor type 1; D014667:Vasopressins; D053829:Amyloid Precursor Protein Secretases; D016282:Aspartic Acid Endopeptidases; C509280:BACE1 protein, human